The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Open accessAbstract
Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor. Here we characterize the diarylthiohydantoins RD162 and MDV3100, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. RD162 and MDV3100 are orally available and induce tumor regression in mouse models of castration-resistant human prostate cancer. Of the first 30 patients treated with MDV3100 in a Phase I/II clinical trial, 13 of 30 (43%) showed sustained declines (by >50%) in serum concentrations of prostate-specific antigen, a biomarker of prostate cancer. These compounds thus appear to be promising candidates for treatment of advanced prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ability of these molecules to inhibit AR transcriptional activity and demonstrate clinical efficacy in a phase I/II trial of patients with CR tumors, in the case of MDV 3100, suggests that ligand-directed therapeutics might still have a place in future treatment regimes.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [81]
In the citing paper
“The ability of these molecules to inhibit AR transcriptional activity and demonstrate clinical efficacy in a phase I/II trial of patients with CR tumors, in the case of MDV 3100, suggests that ligand-directed therapeutics might still have a place in future treatment regimes.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [81]
In the citing paper
“EPI-001 targets the NTD of the AR (80), whereas MDV 3100 binds to the LBD (81), similarly to bicalutamide.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [81]
In the citing paper
“The ARE repeat reporter (4X-ARE, firefly luciferase) has been previously described (Tran et al., 2009).”
From Allosteric interactions prime androgen receptor dimerization and activation (2022) · cites this paper as Tran et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,759
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Self-citationScher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citationStructural basis for antagonism and resistance of bicalutamide in prostate cancer
Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E., & Dalton, J. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500381102 · Cited by 426
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
Taplin, M., & Balk, S. P. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10653 · Cited by 392
Larson, S. M., Morris, M. J., Guenther, I., Beattie, B., Humm, J. L., Akhurst, T., Finn, R. D., Erdi, Y. E., Pentlow, K. S., Dyke, J., et al. (2004) · PubMed · Cited by 298
Self-citationMasiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203310200 · Cited by 240
Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T., & Ogawa, O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0817 · Cited by 178
Hodgson, M. C., Astapova, I. I., Cheng, S., Lee, L. J., Verhoeven, M. C., Choi, E., Balk, S. P., & Hollenberg, A. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408972200 · Cited by 143
Homozygous Deletions and Recurrent Amplifications Implicate New Genes Involved in Prostate Cancer
Liu, W., Xie, C., Zhu, Y., Li, T., Sun, J., Cheng, Y., Ewing, C. M., Dalrymple, S. L., Turner, A. R., Sun, J., et al. (2008) · Neoplasia · doi:10.1593/neo.08428 · Cited by 128
Flagged first, then by citations
1 of the 21 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Larson S. M., et al.., J. Nucl. Med. 45, 366 (2004).15001675
Cited by
Sorted by citations
Items 701–800 of 1,000
Circular RNAs in prostate cancer: Biogenesis, biological functions, and clinical significance
Liu, X., Tong, Y., Ding, X., Peng, E., Yang, X., Liu, H., Ye, T., Wang, X., He, Y., Ye, Z., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.10.017 · Cited by 35
Small Molecule Inhibitors as Probes for Estrogen and Androgen Receptor Action
Shapiro, D. J., Mao, C., & Cherian, M. T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.203026 · Cited by 35
Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats
Kim, T., Jeong, J., Song, J., Lee, K., Ahn, S., Ahn, S., Kim, S., & Koo, T. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0592-9 · Cited by 35
Sakkiah, S., Ng, H. W., Tong, W., & Hong, H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1192131 · Cited by 35
Effect of N‐methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide
Pang, X., Peng, L., & Chen, Y. (2017) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3516 · Cited by 35
Self-citationAntiandrogenic Activity of Resveratrol Analogs in Prostate Cancer LNCaP Cells
Iguchi, K., Toyama, T., Ito, T., Shakui, T., Usui, S., Oyama, M., Iinuma, M., & Hirano, K. (2012) · Journal of Andrology · doi:10.2164/jandrol.112.016782 · Cited by 34
Liu, V., Yau, W., Tam, C. W., Yao, K., & Shiu, S. Y. W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061130 · Cited by 37
Feiersinger, G. E., Trattnig, K., Leitner, P. D., Guggenberger, F., Oberhuber, A., Peer, S., Hermann, M., Skvortsova, I., Vrbková, J., Bouchal, J., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12185 · Cited by 36
Dahiya, N. R., Chandrasekaran, B., Kolluru, V., Ankem, M. K., Damodaran, C., & Vadhanam, M. V. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22848 · Cited by 34
Chung, W.-M., Ho, Y.-P., Chang, W., Dai, Y., Chen, L., Hung, Y., & Ma, W. (2019) · Cancers · doi:10.3390/cancers11040463 · Cited by 34
Tyagi, A., Chandrasekaran, B., Kolluru, V., Rai, S., Jordan, A. C., Alatassi, H., Messer, J. C., Ankem, M. K., Damodaran, C., & Haddad, A. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.03.008 · Cited by 34
G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer
Mukhopadhyay, C., Yang, C., Xu, L., Liu, D., Wang, Y., Huang, D., Deonarine, L. D., Cyrta, J., Davicioni, E., Sboner, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27024-x · Cited by 35
Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
Sanford, M. (2013) · Drugs · doi:10.1007/s40265-013-0129-9 · Cited by 34
Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
Balasubramaniam, S., Comstock, C. E. S., Ertel, A., Jeong, K. W., Stallcup, M. R., Addya, S., McCue, P. A., Ostrander, W. F., Augello, M. A., & Knudsen, K. E. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3049 · Cited by 34
New Strategies Against Prostate Cancer – Pt(II)-Based Chemotherapy
Matos, C. S., de Carvalho, A. L. M. B., Lopes, R. P., & Marques, M. P. M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803306394 · Cited by 34
Current Treatment Strategies for Castration-Resistant Prostate Cancer
Kim, S. J., & Kim, S. I. (2011) · Korean journal of urology · doi:10.4111/kju.2011.52.3.157 · Cited by 34
Morris, M. J., Rathkopf, D. E., Novotny, W. F., Gibbons, J. A., Peterson, A., Khondker, Z., Ouatas, T., Scher, H. I., & Fleming, M. T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2638 · Cited by 34
Self-citationSantis, M. D., & Fred Saad, C. (2016) · Urology · doi:10.1016/j.urology.2016.02.010 · Cited by 34
Yu, Z., He, S., Wang, D., Patel, H., Miller, C. P., Brown, J. L., Hattersley, G., & Saeh, J. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0670 · Cited by 34
Novel agents for castration‐resistant prostate cancer: Early experience and beyond
Fujimoto, N. (2015) · International Journal of Urology · doi:10.1111/iju.12907 · Cited by 33
Kregel, S., Szmulewitz, R. Z., & Griend, D. J. V. (2014) · The Prostate · doi:10.1002/pros.22870 · Cited by 33
MDV3100 for the treatment of prostate cancer
Mukherji, D., Pezaro, C. J., & Bono, J. S. D. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.651125 · Cited by 33
Sadar, M. D. (2011) · World Journal of Urology · doi:10.1007/s00345-011-0745-5 · Cited by 33
Low-dose diethylstilbestrol for the treatment of advanced prostate cancer
Clemons, J., Glodé, L. M., Gao, D., & Flaig, T. W. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.12.004 · Cited by 33
Endocrine prevention and treatment of prostate cancer
Tammela, T. L. J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.03.002 · Cited by 33
Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial
Fred Saad, C., Bono, J. S. D., Shore, N. D., Fizazi, K. S., Loriot, Y., Hirmand, M., Franks, B., Haas, G. P., & Scher, H. I. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.025 · Cited by 33
Self-citationChism, D. D., Silva, D. D., & Whang, Y. E. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.928594 · Cited by 33
Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer
Asangani, I. A., Blair, I. A., Duyne, G. D. V., Hilser, V. J., Moiseenkova‐Bell, V. Y., Plymate, S. R., Sprenger, C. C. T., Wand, A. J., & Penning, T. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.012411 · Cited by 34
Signaling Pathways That Control Apoptosis in Prostate Cancer
Ali, A. A., & Kulik, G. (2021) · Cancers · doi:10.3390/cancers13050937 · Cited by 34
McKay, R. R., Kwak, L., Crowdis, J. P., Sperger, J. M., Zhao, S. G., Xie, W., Werner, L. L., Lis, R. T., Zhang, Z., Wei, X. X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4616 · Cited by 33
Hu, J., Aprikian, A. G., Vanhuyse, M., & Dragomir, A. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.08.009 · Cited by 33
Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer
Hou, Z., Huang, S., Mei, Z., Chen, L., Guo, J., Gao, Y., Zhuang, Q., Zhang, X., Tan, Q., Yang, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100561 · Cited by 33
Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
Siemińska, I., & Baran, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.862416 · Cited by 33
Wei, L., Gao, H., Yu, J., Zhang, H., Nguyen, T. T. L., Gu, Y., Passow, M. R., Carter, J. M., Qin, B., Boughey, J. C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1016 · Cited by 33
Edman, K., Ahlgren, R., Bengtsson, M., Bladh, H., Bäckström, S., Dahmén, J., Henriksson, K., Hillertz, P., Hulikal, V., Jerre, A., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.070 · Cited by 33
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer
Toren, P., & Gleave, M. E. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.38 · Cited by 33
Poutiainen, P., Oravilahti, T., Peräkylä, M., Palvimo, J. J., Ihalainen, J. A., Laatikainen, R., & Pulkkinen, J. T. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300233k · Cited by 33
Christenson, J. L., Trepel, J. B., Ali, H. Y., Lee, S., Eisner, J. R., Baskin-Bey, E. S., ELIAS, A. D., & Richer, J. K. (2018) · Hormones and Cancer · doi:10.1007/s12672-017-0314-5 · Cited by 34
New Strategies for Medical Management of Castration-Resistant Prostate Cancer
Asmane, I., Céraline, J., Duclos, B., Rob, L., Litique, V., Barthélémy, P., Bergerat, J., Dufour, P., & Kurtz, J. (2011) · Oncology · doi:10.1159/000323495 · Cited by 32
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
Eichholz, A., Ferraldeschi, R., Attard, G., & Bono, J. S. D. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.038 · Cited by 32
New agents and strategies for the hormonal treatment of castration-resistant prostate cancer
Sharifi, N. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.494178 · Cited by 32
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
Antonarakis, E. S., & Armstrong, A. J. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.24 · Cited by 32
Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
El-Amm, J., Patel, N., Freeman, A. T., & Aragon‐Ching, J. B. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s11670 · Cited by 32
Amin, K. S., Jagadeesh, S., Baishya, G., Rao, P. G., Barua, N. C., Bhattacharya, S., & Banerjee, P. P. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0478 · Cited by 32
Current and emerging treatments in the management of castration-resistant prostate cancer
Shapiro, D. M., & Tareen, B. U. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.59 · Cited by 32
A review of estrogen receptor/androgen receptor genomics in male breast cancer
Severson, T., & Zwart, W. T. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0225 · Cited by 32
Dalal, K., Che, M., Que, N. S., Sharma, A., Yang, R., Lallous, N., Borgmann, H., Özistanbullu, D., Tse, R., Ban, F., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0259 · Cited by 33
Imawari, Y., Mimoto, R., Hirooka, S., Morikawa, T., Takeyama, H., & Yoshida, K. (2017) · Cancer Science · doi:10.1111/cas.13459 · Cited by 32
Nerlakanti, N., Yao, J., Nguyen, D. T., Patel, A. K., Eroshkin, A. M., Lawrence, H. R., Ayaz, M., Kuenzi, B. M., Agarwal, N., Chen, Y., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0602 · Cited by 32
Self-citationWen, L. K., Valderrama, A., Costantino, M. E., & Simmons, S. J. (2019) · Europe PMC (PubMed Central) · Cited by 32
Exendin‐4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation
Wenjing, H., Shao, Y., Yu, Y., Huang, W., Feng, G., & Li, J. (2020) · The Prostate · doi:10.1002/pros.23951 · Cited by 32
Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone
Singh, J. K., Hutt, D. M., Tait, B. D., Guy, N. C., Sivils, J. C., Ortiz, N. R., Payan, A. N., Komaragiri, S. K., Owens, J. J., Culbertson, D. S., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.01.008 · Cited by 32
Qin, Z., Ou, S., Xu, L., Sorensen, K., Zhang, Y., Hu, D., Yang, Z., Hu, W., Chen, F., & Prins, G. S. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13826 · Cited by 32
Kulkarni, A. A., Rubin, N., Tholkes, A. J., Shah, S., Ryan, C. J., Lutsey, P. L., Prizment, A. E., & Rao, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100261 · Cited by 32
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
Yehya, A., Ghamlouche, F., Zahwe, A., Zeid, Y., Wakimian, K., Mukherji, D., & Abou-Kheir, W. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.15 · Cited by 35
Hormonal Therapy of Prostate Cancer
Labrie, F. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)82014-x · Cited by 32
Park, Y., Choi, H., & Lee, J. (2010) · Molecules and Cells · doi:10.1007/s10059-010-0136-6 · Cited by 32
Role of targeted therapy in the treatment of advanced prostate cancer
Fizazi, K. S., Sternberg, C. N., Fitzpatrick, J. M., Watson, R. W. G., & Tabesh, M. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09236.x · Cited by 32
Transfusion Indications for Patients with Cancer
Watkins, T. C., Surowiecka, M., & McCullough, J. (2015) · Cancer Control · doi:10.1177/107327481502200106 · Cited by 32
Maintenance of Androgen Receptor Inactivation by S-Nitrosylation
Yu, Q., Dey, A., Purayil, H. T., & Daaka, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1042 · Cited by 32
Muniyan, S., Chen, S.-J., Lin, F., Wang, Z., Mehta, P. P., Batra, S. K., & Lin, M. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.08.002 · Cited by 32
Johnston, P. A., Nguyen, M. M., Dar, J. A., Ai, J., Wang, Y., Masoodi, K. Z., Shun, T., Shinde, S., Camarco, D. P., Hua, Y., et al. (2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.716 · Cited by 32
Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer
Lombard, A. P., Liu, C., Armstrong, C. M., D'Abronzo, L. S., Lou, W., Chen, H., Dall’Era, M., Ghosh, P., Evans, C. P., & Gao, A. C. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.007 · Cited by 32
Guo, J., Ni, L., Liu, Q., Hao, Z., Zhu, G., Wang, X., Wang, H., Pan‐Hammarström, Q., Xu, B., Han, Y., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.04.002 · Cited by 32
Song, J., Kim, T., Jung, J., Kim, N., Ahn, S. H., Hwang, S., Kang, N. S., Yoo, S., & Koo, T. (2014) · Biomedical Chromatography · doi:10.1002/bmc.3127 · Cited by 31
Management of Metastatic Castration-Resistant Prostate Cancer
Mukherji, D., Eichholz, A., & Bono, J. S. D. (2012) · Drugs · doi:10.2165/11633360-000000000-00000 · Cited by 33
Diethylstilboestrol for the treatment of prostate cancer: past, present and future
Turo, R., Smolski, M., Esler, R. C., Kujawa, M., Bromage, S. J., Oakley, N. E., Adeyoju, A., Brown, S. C., Brough, R., Sinclair, A. M., et al. (2013) · Scandinavian Journal of Urology · doi:10.3109/21681805.2013.861508 · Cited by 31
Emerging treatment options for patients with castration‐resistant prostate cancer
George, D. J., & Moul, J. W. (2011) · The Prostate · doi:10.1002/pros.21435 · Cited by 31
Gong, Y., Wang, D., Dar, J. A., Singh, P., Graham, L., Liu, W., Ai, J., Xin, Z., Guo, Y., & Wang, Z. (2012) · Endocrinology · doi:10.1210/en.2012-1841 · Cited by 31
Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment
Aggarwal, R. R., & Ryan, C. J. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0216 · Cited by 31
van Nuland, M., Hillebrand, M. J. X., Rosing, H., Schellens, J. H. M., & Beijnen, J. H. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000387 · Cited by 31
Wardley, A. M., Cortés, J., Provencher, L., Miller, K. D., Chien, A. J., Rugo, H. S., Steinberg, J., Sugg, J. E., Tudor, I. C., Huizing, M. T., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06109-7 · Cited by 31
Biomarkers for determination prostate cancer: implication for diagnosis and prognosis
Žiaran, S., Nováková, Z. V., Böhmer, D., & Danišovič, Ľ. (2015) · Neoplasma · doi:10.4149/neo_2015_082 · Cited by 34
Knowles, S. M., Tavaré, R., Zettlitz, K. A., Rochefort, M. M., Salazar, F. B., Jiang, Z. K., Reiter, R. E., & Wu, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1452 · Cited by 33
Wang, Y., Radhakrishnan, D., He, X., Peehl, D. M., & Eng, C. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3490 · Cited by 31
Aldol derivatives of Thioxoimidazolidinones as potential anti-prostate cancer agents
Khatik, G. L., Kaur, J., Kumar, V., Tikoo, K., Venugopalan, P., & Nair, V. A. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.04.050 · Cited by 31
CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem
Racioppi, L. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.004 · Cited by 32
Lallous, N., Leblanc, E., Munuganti, R. S. N., Hassona, M. D. H., Nakouzi, N. A., Awrey, S. J., Morin, H., Roshan‐Moniri, M., Singh, K., Lawn, S. O., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0354 · Cited by 31
Devlin, N. J., Herdman, M. J., Pavesi, M., Phung, D., Naidoo, S., Beer, T. M., TOMBAL, B. F., Loriot, Y., Ivanescu, C., Parli, T., et al. (2017) · Health and Quality of Life Outcomes · doi:10.1186/s12955-017-0704-y · Cited by 31
Self-citationReview: Castration-resistant prostate cancer: new science and therapeutic prospects
Joaquim Bellmunt, B., & Oh, W. K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009359769 · Cited by 31
Novel agents and new therapeutics in castration-resistant prostate cancer
Wu, Y., Rosenberg, J. E., & Taplin, M. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283449400 · Cited by 31
Novel drugs targeting the androgen receptor pathway in prostate cancer
Mateo, J., Smith, A. D., Ong, M., & Bono, J. S. D. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9472-2 · Cited by 31
O’Neill, D. J., Jones, D. L., Wade, M., Grey, J., Nakjang, S., Guo, W., Cork, D. M. W., Davies, B. R., Wedge, S. R., Robson, C. N., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4347 · Cited by 30
Kwilas, A. R., Ardiani, A., Gameiro, S. R., Richards, J., Hall, A. B., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.8274 · Cited by 30
Mizokami, A., Kadono, Y., Kitagawa, Y., Izumi, K., & Konaka, H. (2017) · International Journal of Urology · doi:10.1111/iju.13372 · Cited by 30
Tran, L., Kichenadasse, G., Butler, L. M., Centenera, M. M., Morel, K. L., Ormsby, R. J., Michael, M., Lower, K. M., & Sykes, P. J. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0074 · Cited by 30
Role of androgen receptor splice variants, their clinical relevance and treatment options
Wach, S., Taubert, H. W., & Cronauer, M. V. (2019) · World Journal of Urology · doi:10.1007/s00345-018-02619-0 · Cited by 30
Simon, I., Perales, S., Casado-Medina, L., Martínez, A. R., Garrido-Navas, M. C., Sanz, I. P., Díaz‐Mochon, J. J., Alaminos, C., Lupiañez, P., Lorente, J. A., et al. (2021) · Cancers · doi:10.3390/cancers13061483 · Cited by 33
Li, X., Zhou, D., Cai, Y., Yu, X., Zheng, X., Chen, B., Li, W., Zeng, H., Hassan, M., Zhao, Y. H., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-021-00370-1 · Cited by 30
Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells
Sharma, S. J., Cwiklinski, K., Mahajan, S. D., Schwartz, S. A., & Aalinkeel, R. (2023) · Cancers · doi:10.3390/cancers15030902 · Cited by 30
Current role of diethylstilbestrol in the management of advanced prostate cancer
Bosset, P., Albiges, L. K., Seisen, T., Rouge, T. D. L. M., Phé, V., Bitker, M., & Morgan Rouprêt, A. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11206.x · Cited by 30
Zhang, T., Zhu, J., George, D. J., & Armstrong, A. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.995090 · Cited by 31
Methylation of thePMEPA1gene, a negative regulator of the androgen receptor in prostate cancer
Sharad, S., Ravindranath, L., Haffner, M. C., Li, H., Yan, W., Sesterhenn, I. A., Chen, Y., Ali, A., Srinivasan, A., McLeod, D. G., et al. (2014) · Epigenetics · doi:10.4161/epi.28710 · Cited by 30
Self-citationWhat is the pathophysiology of a hormone-resistant prostate tumour?
TOMBAL, B. F. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70163-0 · Cited by 30
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
Qiao, Y., Feng, F. Y.-C., Wang, Y., Cao, X., Han, S., Wilder-Romans, K., Navone, N. M., Logothetis, C. J., Taichman, R. S., Keller, E. T., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2015.11.009 · Cited by 30
Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib
Ji, W., Shi, Y., Wang, X., He, W., Tang, L., Tian, S., Jiang, H., Shu, Y., & Guan, X. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.30572 · Cited by 30
Dysregulated Transcriptional Control in Prostate Cancer
Baumgart, S. J., Nevedomskaya, E., & Haendler, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122883 · Cited by 30
Sun, J., Hu, X., Gao, Y., Tang, Q., Zhao, Z., Xi, W., Yang, F., Zhang, W., Song, Y., Song, B., et al. (2019) · Aging · doi:10.18632/aging.102482 · Cited by 29
Landmarks in hormonal therapy for prostate cancer
Hammerer, P. G., & Stephan Madersbacher, A. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11431.x · Cited by 29
Emerging therapies in castration resistant prostate cancer.
Thoreson, G. R., Gayed, B. A., Chung, P. H., & Raj, G. V. (2014) · PubMed · Cited by 29
Metadata
- Authors
- Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C. D., Higano, C. S., Beer, T. M., Hung, D. T., Scher, H. I., Jung, M. E., & Sawyers, C. L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- University of Washington (US)
- Oregon Health & Science University (US)
- Medivation, Inc. (United States) (US)
- Corresponding author
- Tran, Chris
- Ouk, Samedy
- Chen, Charlie Degui
- Jung, Michael E.
- Sawyers, Charles L.
- ORCID
- Venue
- Science
- Published
- 2009-05-08
- Volume
- 324
- Issue
- 5928
- Pages
- 787-790
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2981508
- OpenAlex
- W2119504728
- Cited by
- 2,292
- References
- 21
- Citations by year
- 2026: 58 · 2025: 91 · 2024: 110 · 2023: 141 · 2022: 139 · 2021: 150 · 2020: 152 · 2019: 131 · 2018: 146 · 2017: 145 · 2016: 157 · 2015: 134 · 2014: 163 · 2013: 163 · 2012: 160
- FWCI
- 116.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA092629)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- castration-resistant prostate cancer, androgen receptor antagonists, enzalutamide, androgen receptor, bicalutamide, nonsteroidal antiandrogens, androgen receptor nuclear translocation, coactivator recruitment, prostate-specific antigen, oral anticancer drugs, drug development
- MeSH terms
- Androgen Antagonists, Anilides, Animals, Antineoplastic Agents, Benzamides, Biological Availability, Cell Nucleus, DNA, Drug Screening Assays, Antitumor, Humans, Male, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Receptors, Androgen, Tosyl Compounds, Transcription, Genetic, Gene Expression Regulation, Neoplastic, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
